NASDAQ:EVO - Nasdaq - US30050E1055 - ADR - Currency: USD
Taking everything into account, EVO scores 2 out of 10 in our fundamental rating. EVO was compared to 56 industry peers in the Life Sciences Tools & Services industry. Both the profitability and financial health of EVO have multiple concerns. EVO is quite expensive at the moment. It does show a decent growth rate.
Industry Rank | Sector Rank | ||
---|---|---|---|
ROA | -10.25% | ||
ROE | -20.59% | ||
ROIC | N/A |
Industry Rank | Sector Rank | ||
---|---|---|---|
OM | N/A | ||
PM (TTM) | N/A | ||
GM | 14.41% |
Industry Rank | Sector Rank | ||
---|---|---|---|
Debt/Equity | 0.41 | ||
Debt/FCF | N/A | ||
Altman-Z | 0.83 |
Industry Rank | Sector Rank | ||
---|---|---|---|
Current Ratio | 1.98 | ||
Quick Ratio | 1.89 |
Industry Rank | Sector Rank | ||
---|---|---|---|
PE | N/A | ||
Fwd PE | N/A |
Industry Rank | Sector Rank | ||
---|---|---|---|
P/FCF | N/A | ||
EV/EBITDA | 45.48 |
Industry Rank | Sector Rank | ||
---|---|---|---|
Dividend Yield | N/A |
4.29
+0.06 (+1.42%)
Industry Rank | Sector Rank | ||
---|---|---|---|
Dividend Yield | N/A |
Industry Rank | Sector Rank | ||
---|---|---|---|
PE | N/A | ||
Fwd PE | N/A | ||
P/S | 1.68 | ||
P/FCF | N/A | ||
P/OCF | 73.52 | ||
P/B | 1.41 | ||
P/tB | 2.08 | ||
EV/EBITDA | 45.48 |
Industry Rank | Sector Rank | ||
---|---|---|---|
ROA | -10.25% | ||
ROE | -20.59% | ||
ROCE | N/A | ||
ROIC | N/A | ||
ROICexc | N/A | ||
ROICexgc | N/A | ||
OM | N/A | ||
PM (TTM) | N/A | ||
GM | 14.41% | ||
FCFM | N/A |
Industry Rank | Sector Rank | ||
---|---|---|---|
Debt/Equity | 0.41 | ||
Debt/FCF | N/A | ||
Debt/EBITDA | 14.13 | ||
Cap/Depr | 130.13% | ||
Cap/Sales | 16.59% | ||
Interest Coverage | N/A | ||
Cash Conversion | 65.54% | ||
Profit Quality | N/A | ||
Current Ratio | 1.98 | ||
Quick Ratio | 1.89 | ||
Altman-Z | 0.83 |